|

Akt/ERK Inhibitor ONC201 Clinical Trials

1 actively recruiting trial across 1 location

▼ -1 trial since August 2026

Also known as: ONC-201, ONC201, TIC10

Pipeline

Phase 2: 1

Top Sponsors

  • Ira Winer1

Indications

  • Malignant Ovarian Epithelial Tumor1
  • Refractory Primary Peritoneal Carcinoma1
  • Refractory Fallopian Tube Carcinoma1
  • Recurrent Ovarian Carcinoma1
  • Platinum-Resistant Primary Peritoneal Carcinoma1

Detroit, Michigan1 trial

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.